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Hyperurikemiaan liittyvän oksidatiivisen stressin on esitetty edistävän prostatan hyvänlaatuista 
liikakasvua (BPH). Ei tiedetä, olisiko antihyperurikemisella lääkityksellä vaikutusta BPH riskiin. 
Tutkimme BPH:n ja antihyperurikemisen allopurinolin käytön yhteyttä. 
 
Kohortin muodostavat 74,745 miestä, jotka on alun perin identifioitu suomalaiseen eturauhassyövän 
seulontatutkimukseen (FinRSPC). Suljimme pois miehet, joilla oli BPH seurannan alussa. 
Käytimme Cox:n regressiomallia verrataksemme BPH lääkityksen, diagnoosin tai leikkauksen 
riskiä allopurinolin käytön mukaan. Lääkekäyttöä analysoitiin aikariippuvaisena muuttujana 
minimoidaksemme kuolemattomuusharhan vaikutusta. 
 
Allopurinolin käyttäjillä oli ei-käyttäjiä pienempi riski kaikille BPH päätetapahtumille: 
monivakioidussa analyysissä BPH lääkityksen (HR 0.81; 95% CI 0.75-0.88), kirjatun BPH 
diagnoosin (HR 0.78; 95% CI 0.71-0.86) ja BPH leikkauksen (HR 0.67; 95% CI 0.58-0.76) riskit 
olivat alhaisemmat ei-käyttäjiin verrattuna. Painoindeksi (BMI) muokkasi riskisuhdetta; 
allopurinolin käyttö oli yhteydessä madaltuneeseen BPH riskiin vain miehillä, joiden painoindeksi 
oli tutkimusväestön mediaanin (27,3 kg/m2) yläpuolella; interaktioiden p-arvo < 0.05 kaikille 
päätetapahtumille. 
 
Mahdollinen selitys voisi olla antihyperurikemisen allopurinolin antioksidatiivinen vaikutus tai 
ksantiinioksidaasientsyymin toiminnan esto. 
 
 
 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityChek-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti.  
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1 ABSTRACT 
 
1.1 Background 
 
Metabolic syndrome and obesity are linked with hyperuricemia, and it has also been proposed that 
oxidative stress associated with hyperuricemia may promote benign prostatic hyperplasia (BPH). 
However, it is currently unknown whether use of antihyperuricemic medication is associated with 
risk of developing BPH. We studied the association between BPH and use of antihyperuricemic 
allopurinol in a Finnish population-based cohort. 
 
1.2 Methods 
 
The study cohort consisted of 74,754 men originally identified for the Finnish Randomized Study of 
Screening for Prostate Cancer (FinRSPC). Information on gout and BPH medication usage (5a-
reductase inhibitors, 5ARIs) during 1996-2014 was obtained from the national medication 
reimbursement database. Information on BPH diagnoses from in- and outpatient hospital visits and 
BPH-related surgery was obtained from the National Health Care Registry. Men with a record of 
BPH at baseline were excluded. We used Cox regression to analyze risk of starting BPH 
medication, having a recorded diagnosis or undergoing BPH surgery by allopurinol use with 
adjustment for age and simultaneous use of statins, antidiabetic or antihypertensive drugs and 
aspirin or other NSAIDs. Medication use was analyzed as a time-dependent variable to minimize 
immortal time bias. 
 
1.3 Results 
 
Men using allopurinol had a decreased risk for all three BPH endpoints: BPH medication (HR 0.81; 
95% CI 0.75-0.88), BPH diagnosis (HR 0.78; 95% CI 0.71-0.86) and BPH-related surgery (HR 
0.67; 95% CI 0.58-0.76) after multivariable adjustment. The risk association did not change by 
cumulative use. The risk decrease disappeared after one to two years lag time. Only BMI modified 
the risk association; the risk decrease was observed only among men with BMI above the median 
(27.3 kg/m2); p for interaction < 0.05 for each endpoint. 
 
1.4 Conclusions 
 
We found that allopurinol use is associated with lowered risk of BPH medication, diagnosis and 
surgery. A possible explanation could be antioxidative effects of urate-lowering allopurinol.  
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2 INTRODUCTION 
 
Benign Prostatic Hyperplasia (BPH) is a common problem among elderly men, but the etiology is 
partly unclear. Age is an established risk factor, but knowledge on modifiable risk factors is limited. 
Some studies have suggested that metabolic syndrome (MBS) and related hyperinsulinemia may 
together increase the risk of BPH – but results are inconsistent (1). Also type II diabetes and treated 
hypertension might be risk factors for BPH. (2) 
 
Gout and hyperuricemia have been reported to associate with chronic inflammation and with 
oxidative stress, and there is some evidence that these factors are connected to prostate cancer and 
possibly also to BPH. (3,4) Oxidative stress has been suggested to be of importance in BPH 
pathogenesis. (5) In vitro uric acid accelerates prostate cancer cell growth. (6) In epidemiological 
studies prostate cancer and BPH seem to share risk factors. (7) Gout patients have been reported to 
have increased risk of urological cancers. (8) In rats allopurinol reduces oxidative stress in the 
prostate (9). Thus, in theory, allopurinol could reduce risk of BPH by reducing oxidative stress 
associated with obesity and hyperuricemia. 
 
Xanthine oxidase is the main enzyme for uric acid formation and it can also oxidize nicotinamide 
adenine dinucleotide (NADH), which induces formation of reactive oxygen species (ROS). (10) 
Allopurinol Inhibits xanthine oxidase, thus lowering oxidative stress. (11) Allopurinol is the main 
antihyperuricemic drug in clinical use, although before 2014 also probenecid was used in Finland 
for the same indication. Mechanism of action differs between the two drugs, probenecid increases 
uric acid clearance (12). 
 
Gout is associated with obesity, which is also associated with an increased BPH risk (13). However, 
it is unknown whether a direct association exists between gout and BPH. The role of hyperuricemia 
in the risk association between obesity and BPH has not been established. Furthermore, it is not 
known whether us of antihyperuricemic drugs, such as antioxidative allopurinol might affect the 
risk or severity of BPH. 
 
We evaluated the association of antihyperuricemic medication usage and BPH in a population-
based cohort study.  
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3 MATERIALS AND METHODS 
 
3.1 Study cohort 
 
Our study cohort comprises of men 55-67 years old at baseline, originally identified for the Finnish 
Randomized Study of Screening for Prostate Cancer (FinRSPC) in 1996-1999. (14) In total 80,458 
men living in metropolitan areas of Helsinki and Tampere were identified from Population Register 
Centre and randomized either to undergo PSA screening at four year intervals or to be followed up 
through national registries. Prevalent prostate cancer cases at baseline were excluded. 
  
The study cohort was linked to the national health care registry (HILMO) maintained by the 
National Institute for Health and Welfare. HILMO records all diagnoses and procedures during in- 
and outpatient hospital visits at Finnish health care units. Diagnoses made in the primary health care 
are not recorded. 
 
All men with a recorded BPH diagnosis from in- and outpatient hospital visits (ICD-10 Code N40), 
BPH surgery (KED00, KED10, KED22, KED33, KED52, KED62, KED72 and KED76) or BPH 
medication (5a-reductase inhibitors, 5ARIs) purchases registered before the screening trial baseline 
at 1996-1999 were excluded, leaving a cohort of 74,754 men without clinical BPH interventions at 
baseline. 
 
Men in the FinRSPC screening arm were mailed a questionnaire in 2004-2008, which included 
questions on height and weight (15). These were used to calculate BMI. The information was 
available for 11,220 men. 
 
3.2 Information on antihyperuricemic medication use 
 
Information on antihyperuricemic drug purchases during years 1995-2014 were obtained from 
national prescription database maintained by the Social Insurance Institution of Finland, SII. 
As a part of national health insurance SII reimburses 50-100% of the price of physician-prescribed 
drug purchases depending on the indication and severity of the condition indicating the drug use. 
The reimbursement is most often received as a price compensation at pharmacy. All Finnish 
citizens are entitled for the compensation. Each reimbursed drug purchase is recorded by the 
prescription database. Antihyperuricemic drugs are available in Finland only through a physician’s 
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prescription, thus comprehensively recorded by the prescription database. The register does not 
record medications used during hospital inpatient periods or over-the-counter drugs. 
 
Information from the prescription database includes the date, dose, package size, and number of 
packages for each purchase. The linkage to study cohort was carried out using personal 
identification number. Information on purchases of antihyperuricemic, BPH, antidiabetic, 
antihypertensive and cholesterol-lowering drugs as well as physician-prescribed purchases of 
NSAIDs and aspirin were extracted from the registry. Drug identification was based on drug-
specific ATC codes. 
 
For each calendar year, we calculated cumulative yearly total amount (doses), duration (number or 
years with recorded medication purchases regardless of the amount) and intensity (average number 
of doses per year of usage) of antihyperuricemic medication use. The yearly number of doses was 
calculated by dividing the yearly mg amount of a given drug with the drug-specific Defined Daily 
Dose (DDD) as listed by the WHO. (16) 
 
3.3 Statistical analyses 
 
Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence 
intervals (95% CI) separately for BPH medication use, BPH diagnosis and BPH surgery. The 
follow-up started at the FinRSPC baseline in 1996-1999 and continued until death, emigration, end 
of 2014 or first occurrence of the BPH endpoints. Time-metric was years and months since the 
FinRSPC baseline. 
 
We use two different model adjustments to estimate BPH risk: age-adjusted and multivariable-
adjusted model with further adjustment for use of statins, antidiabetic drugs, antihypertensive drugs, 
NSAIDs and aspirin. 
 
Antihyperuricemic medication use was analyzed as time-dependent variable; user status, cumulative 
amount and duration of use and average yearly dose were updated prospectively for each follow-up 
year based on yearly recorded medication purchases. 
 
Long term effects of medication use were evaluated in lag time analyses, where medication usage 
was lagged forward in the follow-up time and analyzed 1 to 3 years later than purchased 
independent of later usage. For example, medication purchases in 2002 were analyzed at 2005 in 3-
 9 
year lag time analysis. As information on gout medication use was available since 1995, usage 
before that time was assumed to be at the same level as in 1995. 
 
In subgroup analyses possible risk modification by the background variables was estimated by 
stratifying the study population and testing statistical significance of interaction terms between the 
tested background variable and BPH risk. Effect modification was tested for BMI and NSAID use, 
as both are associated with gout and prostate cancer (17,18), possibly also with BPH.  
 
Statistical significance of the observed differences in background characteristics were compared 
between users and non-users of antihyperuricemic drugs using Chi-square statistics (categorical 
variables) and Mann-Whitney U-test (continuous variables). All reported p-values are two-sided.  
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4 RESULTS 
 
4.1 Population characteristics 
 
A total of 9,015 men (12.1% of the cohort) had any antihyperuricemic medication use. Median 
follow-up time for any endpoint did not differ by antihyperuricemic medication use. Overall, the 
incidence if BPH endpoints was comparable between the users and non-users. Men using 
antihyperuricemic medication were also more often using other drugs: antihypertensive drugs 
(87.9% vs 63.9% among the users and non-users, respectively; p<0.05), antidiabetic drugs (32.4% 
vs 18.4%; p<0.05), cholesterol-lowering drug (57.2% vs 39.8%; p<0.05), NSAIDs (91.6% vs 
76.9%; p<0.05) and aspirin (19.9% vs 15.0%; p<0.05). (TABLE 1) 
 
4.2 Risk of BPH by antihyperuricemic drug use 
 
Antihyperuricemic medication use was associated with decreased risk of starting BPH medication 
(age-adjusted HR 0.90; 95% CI 0.83-0.97, multivariable-adjusted HR 0.81; 95% CI 0.75-0.88). 
Also risk of BPH diagnosis was lower in antihyperuricemic drug users: (HR 0.85; 95% CI 0.77-
0.93) age adjusted and (HR 0.78; 95% CI 0.71-0.86) multivariable adjusted. Strongest risk decrease 
was observed for BPH surgery; (HR 0.72; 95% CI 0.63-0.83) age adjusted and (HR 0.67 95% CI 
0.58-0.76) multivariable adjusted. (TABLE 2) 
No clear risk trends were observed by cumulative amount, years or intensity of antihyperuricemic 
drugs use for any BPH endpoint, although the risk estimates were protective in all strata of 
cumulative use (TABLE 2). 
 
4.3 Long-term risk association between antihyperuricemic drugs and BPH 
 
In lag time analyses the decreased risk for all BPH endpoints disappeared within two years after 
antihyperuricemic drug usage. The decreased risk of BPH diagnosis attenuated already one year 
after the usage. (TABLE 3). 
 
4.4 Subgroup analyses 
 
NSAID use did not modify the risk association between antihyperuricemic medication use and risk 
of BPH medication, BPH diagnosis, or BPH surgery. BMI did modify the risk association; only 
among men with BMI above the median (27.3kg/m2) users of antihyperuricemic drugs had lowered 
 11 
risk of all BPH endpoints (p for interaction 0.008 (medication), 0.025 (diagnosis), and 0.001 
(surgery)) (TABLE 4). 
 
4.5 Sensitivity analyses 
 
During the study period only two gout drugs were in use, allopurinol and probenecid. 
Antihyperuricemic drug use observed in our study consisted almost entirely of allopurinol use, as 
there were only 67 men using probenecid. Analysis limited to probenecid users only showed no risk 
difference for BPH between the users and non-users (Supplementary table).  Therefore, the 
observed risk decrease by antihyperuricemic drug use are due to allopurinol.
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5 DISCUSSION 
 
Despite gout and BPH occurring in the same age group, to our knowledge, this is the first study to 
estimate the risk association between the use of allopurinol and BPH. Risk for BPH was found to be 
lower in men who use allopurinol compared to non-users. The finding is unexpected, as men with 
gout often have risk factors for BPH, such as obesity. One explanation for the association could be 
that the most commonly used antihyperuricemic drug, allopurinol, has also antioxidant effects (19). 
The risk decrease was stronger in men with BMI above the median (27.3kg/m2), i.e. among men 
with presumably higher risk for BPH. Thus allopurinol may lower the increased risk of BPH among 
overweight men by decreasing oxidative stress and chronic inflammation related to obesity (20). To 
our knowledge, possible beneficial effects of allopurinol against prostatic disease has not been 
previously estimated in epidemiological studies. Our study supports the benefits of 
antihyperuricemic drug use as it was associated with decreased risk for all three BPH endpoints. 
 
Allopurinol inhibits enzyme xanthine oxidoreductase, which catalyzes the last two reactions in the 
urea cycle: hypoxanthine moving to xanthine and further to uric acid. Uric acid has been associated 
with oxidative stress-related conditions, such as cardiovascular disease. (21) Oxidative stress is also 
a risk factor for BPH. (22) Thus inhibition of xanthine oxidase provides a possible biological 
mechanism for beneficial effects of allopurinol against BPH. 
 
Another possible mechanism for benefits of allopurinol use is systemic lowering of uric acid level. 
Previous laboratory studies have suggested that elevated uric acid level may increase oxidative 
stress in the prostate, whereas allopurinol use may lower it. (6,9) Nevertheless, we did not have 
information on uric acid levels and therefore could not assess its role directly. It has to be 
considered, that the risk decrease could be caused by other background factors. 
 
Possible confounding factor is that medication users, such as allopurinol user, may be more active 
users of health services, with more frequent physician contacts. This may lead to more frequent 
diagnoses of asymptomatic BPH. We could not adjust for this possible confounder as we did not 
have information on prostate volumes. However, this possible confounder would increase the risk 
estimates among allopurinol users, and thus does not limit our inference of decreased BPH risk.  
 
Concordant to previous studies (13), BMI was an effect modifier; the inverse association between 
gout medication and BPH risk was strongest in men with BMI above the median. The finding could 
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be a consequence of the connection between obesity and oxidative stress. (23)  The antioxidant 
effect of allopurinol may be stronger in men with higher level of oxidative stress due to obesity. 
 
Our study has many strengths. Our large study cohort was population-based, collected from Finnish 
national registries and thus free of biases often associated with survey-based cohorts, such as recall 
bias.  Large cohort size minimized the effect of random error. Also, information on three BPH 
endpoints from national health care registries was detailed and reliable.  Information on 
antihyperuricemic medication use from the SII prescription database allowed us to evaluate 
medication use on a year-by-year basis. Additionally, we had extensive information on use of other 
drugs often used together with antihyperuricemic drugs, such as NSAIDs. Thus, we were able to 
control for confounding by medication use for other indications. 
 
Our study also has limitations. Prostate sizes were not available, and our data on BPH relied solely 
on indirect estimators BPH-related procedures, diagnoses and 5a-reductase inhibitor use recorded 
by the registries.  Prevalence of subclinical BPH is high in this age-group, and missing information 
on actual prostate sizes allowed selection bias of more subclinical BPH being detected among men 
contacting a physician due to gout symptoms. Only limited information on BMI was available, and 
we did not have information on lifestyle factors such as diet, smoking and physical activity, which 
could have caused confounding. We aimed to minimize confounding by comorbidities such as 
diabetes by using model adjustments, but residual confounding is always possible. 
 
In conclusion, we observed that use of antihyperuricemic medication was associated with lowered 
risk of starting BPH medication, having BPH diagnosis and undergoing BPH surgery, especially in 
overweight men. The finding supports previous reports of beneficial effects of allopurinol in the 
prostate. If confirmed in further studies, allopurinol may prove to be beneficial against development 
of clinically significant BPH.  
 14 
6 CONFLICT OF INTERESTS 
 
TLJ Tammela: consultant fees from Astellas, Bayer and Roche 
TJ Murtola: consultant fees from Astellasand Janssen Cilag. Lecture fees from Astellas, GSK and 
Janssen Cilag. 
K Taari:  Consultant fee from Abbvie, research funding from Medivation, travel support from 
Astellas, and Orion 
Other authors declare no conflict of interests.  
 15 
7 REFERENCES 
 
1.  Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and 
metabolic syndrome. Nat Rev Urol. 2016 Feb;13(2):108–19.  
2.  Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-
risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 
1998 Mar;1(3):157–62.  
3.  De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression 
of benign prostatic hyperplasia. Nat Rev Urol. 2016 Oct;13(10):613–26.  
4.  Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp 
Clin Cancer Res CR [Internet]. 2016 Sep 8 [cited 2017 Sep 14];35(1). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017015/ 
5.  Vital P, Castro P, Ittmann M. Oxidative stress promotes benign prostatic hyperplasia. The 
Prostate. 2016 Jan;76(1):58–67.  
6.  Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid: a modulator of prostate cells and 
activin sensitivity. Mol Cell Biochem. 2016 Mar;414(1–2):187–99.  
7.  Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat 
Rev Urol. 2013 Jan;10(1):49–54.  
8.  Chen C-J, Yen J-H, Chang S-J. Gout patients have an increased risk of developing most cancers, 
especially urological cancers. Scand J Rheumatol. 2014 Oct;43(5):385–90.  
9.  Castro GD, Costantini MH, Castro JA. Rat ventral prostate xanthine oxidase-mediated 
metabolism of acetaldehyde to acetyl radical. Hum Exp Toxicol. 2009 Apr;28(4):203–8.  
10.  Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, et al. A reappraisal 
of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an 
electron donor. Free Radic Res. 1998 Feb;28(2):151–64.  
11.  Bove M, Cicero AFG, Veronesi M, Borghi C. An evidence-based review on urate-lowering 
treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk 
Manag. 2017;13:23–8.  
 16 
12.  Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. 
Contrib Nephrol. 2005;147:35–46.  
13.  Parikesit D, Mochtar CA, Umbas R, Hamid ARAH. The impact of obesity towards prostate 
diseases. Prostate Int. 2016 Mar;4(1):1–6.  
14.  Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate 
cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013 May 
15;105(10):719–25.  
15.  Sarre S, Määttänen L, Tammela TLJ, Auvinen A, Murtola TJ. Postscreening follow-up of the 
Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and 
mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory 
drug use. Scand J Urol. 2016 Aug;50(4):267–73.  
16.  WHOCC - ATC/DDD Index [Internet]. [cited 2017 Sep 14]. Available from: 
https://www.whocc.no/atc_ddd_index/ 
17.  Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman U-H, Tammela TLJ, et al. Use of 
non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate 
cancer screening trial. The Prostate. 2015 Sep;75(13):1394–402.  
18.  Cao Y, Giovannucci E. Obesity and Prostate Cancer. Recent Results Cancer Res Fortschritte 
Krebsforsch Progres Dans Rech Sur Cancer. 2016;208:137–53.  
19.  Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, et al. Clinical Study on efficacy of 
allopurinol in patients with acute coronary syndrome and its functional mechanism. Hell J 
Cardiol HJC Hell Kardiologike Epitheorese. 2017 Jan 14; (in press) 
20.  Ellulu MS. Obesity, cardiovascular disease, and role of vitamin C on inflammation: a review of 
facts and underlying mechanisms. Inflammopharmacology. 2017 Jun;25(3):313–28.  
21.  Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. 
Curr Pharm Des. 2005;11(32):4145–51.  
22.  Szewczyk-Golec K, Tyloch J, Czuczejko J. Antioxidant defense system in prostate 
adenocarcinoma and benign prostate hyperplasia of elderly patients. Neoplasma. 
2015;62(1):119–23.  
 17 
23.  Rupérez AI, Gil A, Aguilera CM. Genetics of Oxidative Stress in Obesity. Int J Mol Sci. 2014 
Feb 20;15(2):3118–44.  
 
  
 18 
8 TABLES 
8.1 Table 1 
 
Population characteristics by antihyperuricemic drug use. Study cohort of 74 754 men free of BPH 
at baseline. 
 
 
 Antihyperuricemic medication 
 Non-users Users 
N of men 65 739 9 015 
N (%) of BPH medication** 13 115 (20.0%) 1 841 (20.4%) 
N (%) of BPH diagnoses** 8 867 (13.5%) 1 229 (13.6%) 
N (%) of men undergoing BPH 
surgery 
5 079 (7.7%) 648 (7.2%) 
Median (IQR) follow-up until BPH 
medication 
16.0 (10.6-18.0) 16.0 (10.9-17.6) 
Median (IQR) follow-up until BPH 
dg 
16.0 (12.6-18.0) 16.0 (12.6-18.0) 
Median (IQR) follow-up until BPH 
surgery 
16.2 (13.3-18.0) 16.0 (13.2-18.0) 
Median (IQR) age at baseline 59 (55-63) 59 (55-63) 
Median (IQR) BMI 26.1 (24.2-28.7) 28.1 (25.8-31.0)* 
Antihypertensive drug users; n (%) 42 011 (63.9%) 7 922 (87.9%)* 
Antidiabetic drug users; n (%) 12 105 (18.4%) 2 920 (32.4%)* 
Cholesterol-lowering drug users; n 
(%) 
26 167 (39.8%) 5153 (57.2%)* 
NSAID users; n (%) 50 555 (76.9%) 8 262 (91.6%)* 
Aspirin users; n (%) 9 845 (15.0%) 1 794 (19.9%)* 
* P < 0.05 for difference in observed differences compared to non-users. Calculated with Mann-Whitney U-test for 
continuous variables (BMI), chi-square test for categorical variables. 
** BPH diagnoses recorded from secondary health care only, medication use includes also prescriptions from 
primary health care. BPH medication use defined as recorded purchases of either finasteride or dutasteride. 
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8.2 Table 2 
 
Risk of BPH by antihyperuricemic drug use. Study cohort of 74 754 men free of BPH at baseline. 
 
 
  Risk of BPH medication Risk of having recorded 
BPH diagnosis 
Risk of BPH surgery 
 N HR (95% 
CI) Age 
adjusted 
HR (95% 
CI) 
Multivar.adjusted 
HR (95% 
CI) Age 
adjusted 
HR (95% 
CI) 
Multivar.adjusted 
HR (95% 
CI) Age 
adjusted 
HR (95% 
CI) 
Multivar.adjusted 
Gout drug 
use 
       
Non-user 65 739 Ref. Ref. Ref. Ref. Ref. Ref. 
Any user 9 015 0.90 (0.83-
0.97) 
0.81 (0.75-
0.88) 
0.85 (0.77-
0.93) 
0.78 (0.71-
0.86) 
0.72 (0.63-
0.83) 
0.67 (0.58-
0.76) 
Cumulative 
amount 
       
Tertile1 
(DDD 
<125.00) 
3 143 0.88 (0.73-
1.05) 
0.82 (0.68-
0.98) 
0.83 (0.66-
1.04) 
0.78 (0.62-
0.98) 
0.75 (0.54-
1.03) 
0.71 (0.51-
0.98) 
Tertile2 
(DDD 
=125.00-
600.00 
2 924 0.84 (0.74-
0.97) 
0.77 (0.67-
0.88) 
0.87 (0.74-
1.03) 
0.81 (0.68-
0.95) 
0.80 (0.64-
1.01) 
0.74 (0.59-
0.93) 
Tertile3 
(DDD 
>600.00) 
2 948 0.94 (0.84-
1.05) 
0.85 (0.76-
0.95) 
0.84 (0.74-
0.96) 
0.77 (0.67-
0.88) 
0.67 (0.55-
0.81) 
0.61 (0.50-
0.74) 
Cumulative 
years of use 
       
tertile1 
(years <2) 
3 755 0.85 (0.73-
0.99) 
0.79 (0.67-
0.92) 
0.80 (0.66-
0.98) 
0.75 (0.62-
0.92) 
0.75 (0.57-
0.99) 
0.71 (0.53-
0.94) 
Tertile2 
(years 2-6) 
2 681 0.94 (0.82-
1.07) 
0.85 (0.74-
0.97) 
0.86 (0.72-
1.01) 
0.79 (0.67-
0.94) 
0.80 (0.64-
1.01) 
0.74 (0.59-
0.93) 
Tertile3 
(years >6) 
2 579 0.89 (0.79-
1.01) 
0.80 (0.71-
0.91) 
0.86 (0.75-
0.99) 
0.79 (0.69-
0.91) 
0.66 (0.54-
0.81) 
0.60 (0.49-
0.74) 
Average 
intensity of 
use 
       
Tertile1 
(Intensity 
<62.50) 
3 102 0.85 (0.72-
1.02) 
0.79 (0.67-
0.94) 
0.89 (0.73-
1.08) 
0.83 (0.68-
1.01) 
0.71 (0.53-
0.96) 
0.67 (0.50-
0.90) 
Tertile2 
(Intensity 
62.00-
112.50) 
3 001 0.85 (0.74-
0.98) 
0.77 (0.67-
0.89) 
0.84 (0.71-
0.98) 
0.77 (0.66-
0.91) 
0.84 (0.67-
1.03) 
0.77 (0.62-
0.96) 
Tertile3 
(Intensity 
>112.50) 
2 912 0.95 (0.85-
1.06) 
0.85 (0.76-
0.96) 
0.84 (0.73-
0.96) 
0.77 (0.67-
0.89) 
0.64 (0.52-
0.80) 
0.59 (0.47-
0.72) 
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8.3 Table 3 
 
Long-term association between antihyperuricemic drug use and BPH risk. Study cohort of 74 754 
men free of BPH at baseline. 
 
 
 Main analysis HR 
(95 CI) multivar adjusted 
1v lag time multivar 
adjusted 
2v lag time multivar 
adjusted 
3v lag time multivar 
adjusted 
BPH medication 0.81 (0.75-0.88) 0.87 (0.81-0.95) 0.93 (0.86-1.00) 0.92 (0.85-1.00) 
BPH diagnosis 0.78 (0.71-0.86) 0.93 (0.85-1.02) 0.98 (0.90-1.07) 0.96 (0.87-1.05) 
BPH surgery 0.67 (0.58-0.76) 0.85 (0.75-0.96) 0.88 (0.78-1.00) 0.90 (0.79-1.01) 
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8.4 Table 4 
 
Risk of BPH by antihyperuricemic drug use in subgroup analysis stratified by NSAID use and BMI.  
Study cohort of 74 754 men free of BPH at baseline. 
 
 
 BPH medication HR 
(95% CI) age adjusted 
BPH diagnosis HR (95% 
CI) age adjusted 
BPH surgery HR (95% 
CI) age adjusted 
NSAID user 0.84 (0.78-0.91) 0.81 (0.74-0.89) 0.68 (0.59-0.79) 
NSAID non user 0.90 (0.61-1.31) 0.81 (0.51-1.27) 0.98 (0.57-1.69) 
P for interaction 0.712 0.382 0.971 
BMI > median (27.3kg/m2) 0.68 (0.54-0.86) 0.49 (0.36-0.69) 0.55 (0.35-0.87) 
BMI < median (27.3kg/m2) 0.96 (0.68-1.36) 0.90 (0.59-1.37) 1.06 (0.62-1.80) 
P for interaction 0.008 0.025 0.001 
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8.5 Supplementary table 
 
Risk of benign prostatic hyperplasia (BPH) among probenecid users compared to non-users. Study 
cohort of 74 754 men free of BPH at baseline. 
 
 
  Risk of BPH 
medication use 
Risk of having 
recorded BPH 
diagnosis 
Risk of BPH 
surgery 
 N HR (95% CI) 
Multivar.adjusted 
HR (95% CI) 
Multivar.adjusted 
HR (95% CI) 
Multivar.adjusted 
Probenecid use     
Non-user 74 687 Ref. Ref. Ref. 
Any user 67 1.17 (0.38-3.64) 1.03 (0.14-7.28) 1.86 (0.26-13.24) 
 
